Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-23	US$1.710	-2.84%	53,738
26-07-22	US$1.760	-8.81%	57,847
26-07-21	US$1.930	+2.12%	139,103
26-07-20	US$1.890	+12.50%	530,348
26-07-17	US$1.680	+3.70%	273,374

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-23 EDT			5-day change	1st Jan Change
1.710 ^USD	-2.84%		+5.56%	-68.45%

06-30	Exicure, Inc. Announces Board and Committee Changes, Effective June 30, 2026	CI
05-29	Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	10.9M 9.59M 8.91M 8.19M 15.36M 1.06B 15.64M 106M 41.54M 515M 40.92M 40.03M 1.79B	P/E 2024	-2.88x	P/E 2025	-6.9x
Enterprise Value	7.33M 6.45M 5.99M 5.51M 10.33M 710M 10.51M 71.61M 27.93M 346M 27.52M 26.92M 1.2B	EV / Sales 2024	70.2x	EV / Sales 2025	-
Free-Float	57.41%	Yield 2024 *	-	Yield 2025	-

06-30	Exicure, Inc. Announces Board and Committee Changes, Effective June 30, 2026	CI
05-29	Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-22	Exicure announces co-development agreement with Adbiotech for burixafor (GPC-100)	RE
04-22	Exicure, Inc. And Adbiotech Co., Ltd. Enter Co-Development Agreement For Burixafor (GPC-100)	CI
04-10	Exicure, Inc. Announces Management Changes	CI
03-27	Exicure, Inc. Announces Resignation of Director Sangjin Yeo from Board and Audit Committee, Effective March 27, 2026	CI
03-25	Exicure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-24	Exicure, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-17	Exicure appoints Jung Soo Kim as CEO and president	RE
02-17	Exicure, Inc. Announces Executive Appointments, Effective February 11, 2026	CI
02-17	Exicure, Inc. Appoints Gyuyeob Lee as Interim Chief Financial Officer, Effective February 11, 2026	CI
02-17	Exicure, Inc. Appoints Jung Soo Kim as Chief Executive Officer, Effective February 11, 2026	CI
02-10	Exicure, Inc. Announces Resignation of Seung Ik Baik as Chief Financial Officer, Effective February 9, 2026	CI

22-08-16	Chardan Adjusts Exicure's Price Target to $2 on 1-for-30 Reverse Stock Split, Maintains Neutral Rating	MT
22-03-29	Chardan Adjusts Exicure's Price Target to $0.25 From $0.40 'on Increased Dilution;' Neutral Rating Kept	MT
21-12-13	Chardan Downgrades Exicure to Neutral From Buy After Probe Shows Clinical Data Misrepresentation, Lowers PT to $0.40 From $2.25	MT
21-11-23	Chardan Adjusts Price Target on Exicure to $2.25 From $7 'on Uncertain Delays for Clinical Programs,' Keeps Buy Rating	MT
21-05-17	EXICURE : HC Wainwright Adjusts Price Target on Exicure to $6 From $8, Maintains Buy Rating	MT

Exicure, Inc. Stock

Stocks

XCUR

US30205M3097

Biotechnology & Medical Research

Valuation: Exicure, Inc.

Chart: Exicure, Inc.

Latest news : Exicure, Inc.

Analysts' recommendations: Exicure, Inc.

Press Releases: Exicure, Inc.

News in other languages: Exicure, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Exicure, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

06-30	Exicure Announces Board and Committee Changes	AQ
06-10	Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement	AQ
06-01	Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q	AQ
04-22	Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)	AQ
04-02	Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions	AQ

21-08-02	Les valeurs à suivre aujourd'hui à Paris Lundi 2 août 2021
21-08-02	Ipsen : signe un partenariat avec Exicure dans les acides nucléiques sphériques
21-08-02	EN DIRECT DES MARCHES : Axa, Bolloré, Neoen, Ipsen, HSBC, Heineken, Square, Moderna...
21-08-02	Ipsen : accord de collaboration avec Exicure
21-08-02	Dernière ligne droite avant la coupure aoûtienne

1 day	-2.84%
1 week	+5.56%
Current month	-17.79%
1 month	-37.36%
3 months	-53.02%
6 months	-72.24%
Current year	-68.45%

1 week	1.56	2.02
1 month	1.43	2.88
Current year	1.43	6.64
1 year	1.43	9.48
3 years	1.43	36
5 years	1.43	297
10 years	1.43	975

Manager	Title	Age	Since
Jungsoo Kim CEO	Chief Executive Officer	-	2026-02-10
Josephine Cardarelli PSD	President	-	2025-10-05
Gyuyeob Lee DFI	Director of Finance/CFO	40	2026-02-10

Director	Title	Age	Since
Dong-Ho Lee BRD	Director/Board Member	64	2023-08-20
Jungsoo Kim BRD	Director/Board Member	-	2026-02-10
Gyeung Seog Cheon BRD	Director/Board Member	-	2026-02-08

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/8/26	EXICURE HITRON, INC.	Others	Company	117,441	1.8589%
2/16/26	Josh Miller	Tax	Chief Accounting Officer	8	0.0001%
1/21/26	EXICURE HITRON, INC.	Sell	Company	258,367	4.0895%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXICURE, INC.	-2.84%	+5.56%	-79.59%	-68.33%	11.22M
WUXI APPTEC CO., LTD.	+1.23%	-3.08%	+53.96%	+87.98%	55.27B
ARGENX SE	+5.09%	+6.24%	+63.15%	+62.06%	54.15B
INSMED INCORPORATED	+0.72%	-0.05%	+3.84%	+409.54%	23.11B
BIONTECH SE	+0.25%	+0.55%	-19.67%	-15.22%	23.22B
WUXI BIOLOGICS (CAYMAN) INC.	+1.03%	-0.76%	+40.14%	-3.59%	20.33B
GENMAB A/S	-0.37%	+0.42%	+37.47%	-31.61%	17.91B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.87%	-2.80%	+37.96%	+600.00%	15.76B
PHARMAESSENTIA CORPORATION	-2.54%	-12.88%	+168.62%	+289.45%	15B
EXELIXIS, INC.	+1.22%	-0.05%	+22.58%	+182.63%	13.82B
Average	+0.47%	+0.53%	+32.85%	+151.29%	23.86B
Weighted average by Cap.	+1.56%	+1.19%	+45.94%	+138.39%

	2024	2025
Net sales	500K 440K 409K 376K 705K 48.42M 717K 4.89M 1.91M 23.62M 1.88M 1.84M 81.94M	-
Net income	-9.7M -8.53M -7.93M -7.29M -13.67M -939M -13.92M -94.78M -36.97M -458M -36.42M -35.63M -1.59B	-4.95M -4.35M -4.04M -3.72M -6.97M -479M -7.1M -48.32M -18.85M -234M -18.57M -18.17M -811M
Net Debt	-6.46M -5.69M -5.28M -4.86M -9.11M -626M -9.27M -63.16M -24.63M -305M -24.27M -23.74M -1.06B	-3.57M -3.14M -2.92M -2.68M -5.03M -346M -5.12M -34.88M -13.6M -169M -13.4M -13.11M -585M